Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Alon Avidan, MD (ucla)

Description

Summary

This study will enroll participants with idiopathic rapid eye movement (REM) sleep behavior disorder (RBD), for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

Details

REM sleep behavior disorder (RBD) is a rare disorder where people act out their dreams. People with RBD often, but not always, develop Parkinson's Disease, dementia with Lewy bodies, multiple system atrophy, or other neurodegenerative diseases of the synucleinopathy type. The North American Prodromal Synucleinopathy (NAPS) Consortium was formed with the purpose of enrolling participants with RBD, in anticipation of a future clinical trial of a neuroprotective treatment against synucleinopathies. The NAPS Consortium will collect standardized clinical assessments, biofluids, and other data in order to develop biomarkers for synucleinopathies in the prodromal (presymptomatic) stage as well as a trial-ready registry of participants. Participants procedures will include a ~2-hour clinical assessment (medical history and physical exam), questionnaires, blood draw, and (at select sites) optional lumbar puncture.

Keywords

REM Sleep Behavior Disorder Parkinson Disease Lewy Body Disease Dementia With Lewy Bodies Multiple System Atrophy REM Sleep Parasomnias sleep REM rapid eye movement parkinson parasomnia synuclein synucleinopathy Dementia Shy-Drager Syndrome Parasomnias Atrophy Mental Disorders

Eligibility

You can join if…

Open to people ages 18 years and up

  • Idiopathic REM sleep behavior disorder

You CAN'T join if...

  • REM sleep behavior disorder secondary to another cause (ex: narcolepsy, dementia, Parkinson's Disease, etc)
  • Other neurological disorder

Locations

  • University of California Los Angeles accepting new patients
    Los Angeles California 90095 United States
  • Stanford University accepting new patients
    Redwood City California 94063 United States

Lead Scientist at UC Health

  • Alon Avidan, MD (ucla)
    Professor of Clinical , Neurology. Authored (or co-authored) 54 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Washington University School of Medicine
ID
NCT03623672
Study Type
Observational [Patient Registry]
Last Updated